^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AT 009

    i
    Other names: AT 009
    Associations

    News

    Trials
    Company:
    Affitech
    Drug class:
    CXCR4 antagonist
    Related drugs:
    Associations

    News

    Trials
    over2years
    LncRNA NONRATT009773.2 promotes bone cancer pain progression through the miR-708-5p/CXCL13 axis. (PubMed, Eur J Neurosci)
    Moreover, NONRATT009773.2 functioned as a microRNA (miRNA) sponge to absorb miR-708-5p and up-regulated miRNA downstream target CXCL13, which plays fundamental roles in the initiation and maintenance of neuroinflammation and hyperalgesia. Collectively, our current findings indicated that NONRATT009773.2 could be employed as a new therapeutic target for BCP.
    Journal
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    AT 009
    almost5years
    Effect of the traditional Chinese medicine Qi Teng Xiao Zhuo granules on chronic glomerulonephritis rats studied by using long noncoding RNAs expression profiling. (PubMed, Gene)
    The ten lncRNAs might play important roles in the Qi Teng Xiao Zhuo granules treatment of CGN. Key genes, such as Ptprc (protein tyrosine phosphatase, receptor type, C), TOP2a, Fos (FBJ osteosarcoma oncogene), Myc (myelocytomatosis oncogene), etc, may be crucial biomarkers for Qi Teng Xiao Zhuo granules.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha)
    |
    doxorubicin hydrochloride • AT 009